Pharmacokinetic Properties of Intravitreal I-124-Aflibercept in a Rabbit Model Using PET/CT

Purpose: To determine the anatomic characteristics and pharmacokinetic properties of intravitreally-placed aflibercept in a rabbit model. Materials and methods: Four Dutch-belted rabbits underwent intravitreal injection with I-124-aflibercept. Serial imaging with PET/CT imaging was performed on days 0, 2, 5, 7, 14, 21, 28 and 35. Measured radioactivity emission in becquerels/mL was used to calculate the half-lives for aflibercept. Results: I-124 aflibercept was confined within the vitreous cavity for the duration of the study. I-124 aflibercept could be detected in the vitreous cavity until day 28 and the average retention time with standard error after correction for radioactive decay was 4.58 ± 0.07 days. Conclusions: I-124 aflibercept was only visible in the vitreous cavity by PET/CT imaging following intravitreal injection. The retention properties were found to be comparable to those measured by other reported methods.

[1]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[2]  M. Knopp,et al.  PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. , 2011, Investigative ophthalmology & visual science.

[3]  U. Schmidt-Erfurth,et al.  Primary Results of an International Phase III Study Using Intravitreal VEGF Trap-Eye Compared to Ranibizumab in Patients with Wet AMD (VIEW 2) , 2011 .

[4]  A. Ho,et al.  Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Efficacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study , 2011 .

[5]  Effect of contact lens power on optical coherence tomography of the retinal nerve fiber layer. , 2011, Investigative ophthalmology & visual science.

[6]  M. Knopp,et al.  positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results , 2010 .

[7]  N. Eter,et al.  Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. , 2008, American journal of ophthalmology.

[8]  J. Roider,et al.  Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. , 2008, Investigative ophthalmology & visual science.

[9]  J. Pulido,et al.  Pharmacokinetics of intravitreal ranibizumab (Lucentis). , 2007, Ophthalmology.

[10]  J. Pulido,et al.  Pharmacokinetics of intravitreal bevacizumab (Avastin). , 2007, Ophthalmology.

[11]  E. Koehler-Stec,et al.  Pharmacokinetics and ocular tissue penetration of VEGF trap after intravitreal injection in rabbits , 2006 .

[12]  G. Chader,et al.  PHARMACOLOGY OF THE EYE , 1984, Handbook of Experimental Pharmacology.